Nexelis Europe
0744.498.061 · rovalta.com · 26/09/2026
ACTIVE
Nexelis Europe
Financial year 2025 · Closed on 31/12/2025
Net result-220,1 k €+23,6 %over 1 year
Gross margin-6,2 k €-69,5 %over 1 year
Equity-1 M €-26,9 %over 1 year
Overview
Identity
Source · BCE/KBONexelis Europe is a Private limited company incorporated in 2020. Its registered office is in Charleroi.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0744.498.061
- Incorporation
- 26/02/2020
- Legal form
- Private limited company
- Registered office
- Rue Clément Ader 10
6041 Charleroi · WallonieSee on map - Contributed capital
- 5 000,00 €
- Latest accounts
- 31/12/2025
Financials
Source · NBB, 5 filingsTrend over 5 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | -6,2 k € | -69.5% | -3,7 k € | +30.7% | -5,3 k € | -58.0% | -3,4 k € | +66.1% | -9,9 k € |
| EBITDA | -6,2 k € | -69.5% | -3,7 k € | +30.7% | -5,3 k € | -58.0% | -3,4 k € | +67.2% | -10,2 k € |
| Operating result | -6,2 k € | -69.5% | -3,7 k € | +30.7% | -5,3 k € | -58.0% | -3,4 k € | +67.2% | -10,2 k € |
| Net result | -220,1 k € | +23.6% | -288,2 k € | -8.6% | -265,5 k € | -131% | -114,9 k € | +25.6% | -154,4 k € |
| Balance sheet | |||||||||
| Equity | -1 M € | -26.9% | -818,1 k € | -54.4% | -529,9 k € | -100% | -264,4 k € | -76.9% | -149,4 k € |
| Total assets | 4,6 M € | +0.0% | 4,6 M € | +0.0% | 4,6 M € | +0.0% | 4,6 M € | +0.0% | 4,6 M € |
| Debts | 5,7 M € | +4.0% | 5,5 M € | +5.6% | 5,2 M € | +5.4% | 4,9 M € | +2.4% | 4,8 M € |
Board of directors
Source · NBB, accounts to 31/12/20251 active · 1 ended
Active mandates
Emmanuel Vanderhaegen
ActiveEnded mandates
Frank Swaelens
EndedOther companies at this address
Rue Clément Ader 10 6041 Charleroi| Company | CBE no. |
|---|---|
2 Bridge WL● Active | 1003.906.745 |
3D Fibroscreen● Active | 1022.772.354 |
AdipoPharma Belgique● Active | 1008.146.338 |
ATRYON BELGIUM● Active | 0751.698.530 |
| 0479.250.670 | |
ConvEyXo● Active | 0725.874.259 |
CONVEYXO GROUP● Active | 1016.957.797 |
ELKEDONIA BELGIUM● Active | 1021.635.177 |
ENDO TOOLS THERAPEUTICS● Active | 0807.570.233 |
Enodia Therapeutics Belgium● Active | 1039.324.811 |
EU BIOTECH CAMPUS● Active | 0776.668.706 |
Exo-Harvest● Active | 0803.425.264 |
Hemastatx● Active | 1019.406.058 |
Immunofusion● Active | 0804.563.629 |
ImmunXperts● Active | 0552.755.587 |
INCHINN THERAPEUTICS● Active | 0799.914.755 |
INSTAR BELGIQUE● Active | 1039.395.085 |
KOKUMA● Active | 0799.078.377 |
LYS MEDICAL● Active | 0688.626.061 |
MILEUTIS● Active | 1011.400.984 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 26/02/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 23 months |
| Filing date | 18/09/2026 | 25/07/2025 | 19/09/2024 | 28/02/2024 | 23/08/2022 |
| General meeting | 11/09/2026 | 30/06/2025 | 12/09/2024 | 30/06/2023 | 20/06/2022 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 5 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 11/09/2026 | 18/09/2026 | French | |
| Abridged model | 31/12/2024 | 30/06/2025 | 25/07/2025 | French | |
| Abridged model | 31/12/2023 | 12/09/2024 | 19/09/2024 | French | |
| Abridged model | 31/12/2022 | 30/06/2023 | 28/02/2024 | French | |
| Abridged model | 31/12/2021 | 20/06/2022 | 23/08/2022 | French |
Valuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20251 active · 1 ended
Active mandates
Emmanuel Vanderhaegen
ActiveEnded mandates
Frank Swaelens
EndedOwnership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Other09/06/2026STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - OBJET
- Other04/06/2026DIVERS
- Restructuring13/03/2026RUBRIQUE RESTRUCTURATION (FUSION, SCISSION, TRANSFERT PATRIMOINE, ETC...)
- Mandates08/01/2026ONTSLAGEN - BENOEMINGEN
- Registered office21/06/2024SIEGE SOCIAL
- Mandates14/02/2023DEMISSIONS, NOMINATIONS
- Mandates31/05/2022DEMISSIONS, NOMINATIONS
- Other20/08/2020STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-220,1 k €↑
- 2024Annual accounts 2024-288,2 k €↓
- 2023Annual accounts 2023-265,5 k €↓
- 2022Annual accounts 2022-114,9 k €↑
- 2021Annual accounts 2021-154,4 k €
- 26/02/2020IncorporationPrivate limited company